title: Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy.
abstract: Because overactivation of the hypothalamic-pituitary-adrenal (HPA) axis occurs in Alzheimer's disease (AD), dysregulation of stress neuromediators may play a mechanistic role in the pathophysiology of AD. However, the effects of stress on tau phosphorylation are poorly understood, and the relationship between corticosterone and corticotropin-releasing factor (CRF) on both β-amyloid (Aβ) and tau pathology remain unclear. Therefore, we first established a model of chronic stress, which exacerbates Aβ accumulation in Tg2576 mice and then extended this stress paradigm to a tau transgenic mouse model with the P301S mutation (PS19) that displays tau hyperphosphorylation, insoluble tau inclusions and neurodegeneration. We show for the first time that both Tg2576 and PS19 mice demonstrate a heightened HPA stress profile in the unstressed state. In Tg2576 mice, 1 month of restraint/isolation (RI) stress increased Aβ levels, suppressed microglial activation, and worsened spatial and fear memory compared with nonstressed mice. In PS19 mice, RI stress promoted tau hyperphosphorylation, insoluble tau aggregation, neurodegeneration, and fear-memory impairments. These effects were not mimicked by chronic corticosterone administration but were prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist. The role for a CRF(1)-dependent mechanism was further supported by the finding that mice overexpressing CRF had increased hyperphosphorylated tau compared with wild-type littermates. Together, these results implicate HPA dysregulation in AD neuropathogenesis and suggest that prolonged stress may increase Aβ and tau hyperphosphorylation. These studies also implicate CRF in AD pathophysiology and suggest that pharmacological manipulation of this neuropeptide may be a potential therapeutic strategy for AD.
authors: Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine and Institute on Aging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
authors: Jenna C
authors: JC
authors: Carroll
authors: Michiyo
authors: M
authors: Iba
authors: Debra A
authors: DA
authors: Bangasser
authors: Rita J
authors: RJ
authors: Valentino
authors: Michael J
authors: MJ
authors: James
authors: Kurt R
authors: KR
authors: Brunden
authors: Virginia M-Y
authors: VM
authors: Lee
authors: John Q
authors: JQ
authors: Trojanowski
mesh_terms: D000818:Animals; D002908:Chronic Disease; D003072:Cognition Disorders / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D007030:Hypothalamo-Hypophyseal System / Q000473:pathology / Q000502:physiology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008822:Mice, Transgenic; D009410:Nerve Degeneration / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D010913:Pituitary-Adrenal System / Q000473:pathology / Q000502:physiology; D018019:Receptors, Corticotropin-Releasing Hormone / Q000096:biosynthesis*; D013315:Stress, Psychological / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D024801:Tauopathies / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D016875:tau Proteins / Q000096:biosynthesis; D000099052:CRF Receptor, Type 1
chemical_list: D018019:Receptors, Corticotropin-Releasing Hormone; D016875:tau Proteins; D000099052:CRF Receptor, Type 1